AAAAI Virtual Annual Meeting. Severity of underlying airways disease and not prior use of corticosteroids posed a risk of more severe COVID-19, a new study finds.
Dupilumab therapy for 4 weeks in adults with severe atopic dermatitis resulted in significant improvements in clinical outcomes with no adverse events reported.
A new modeling study estimates that 64% of US COVID-19 hospitalizations were attributable to at least 1 of 4 pre-existing cardiometabolic conditions.